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Abstract. 
 
Peroxisomal matrix protein import requires 
PEX12, an integral peroxisomal membrane protein 
with a zinc ring domain at its carboxy terminus. Muta-
 
tions in human 
 
PEX12
 
 result in Zellweger syndrome, a 
lethal neurological disorder, and implicate the zinc ring 
domain in PEX12 function. Using two-hybrid studies, 
blot overlay assays, and coimmunoprecipitation experi-
ments, we observed that the zinc-binding domain of 
PEX12 binds both PEX5, the PTS1 receptor, and 
PEX10, another integral peroxisomal membrane pro-
tein required for peroxisomal matrix protein import. 
Furthermore, we identiﬁed a patient with a missense 
mutation in the PEX12 zinc-binding domain, S320F, 
and observed that this mutation reduces the binding of 
PEX12 to PEX5 and PEX10. Overexpression of either 
 
PEX5
 
 or 
 
PEX10
 
 can suppress this 
 
PEX12
 
 mutation, 
providing genetic evidence that these interactions are 
biologically relevant. PEX5 is a predominantly cyto-
plasmic protein and previous PEX5-binding proteins 
have been implicated in docking PEX5 to the peroxi-
some surface. However, we ﬁnd that loss of PEX12 or 
PEX10 does not reduce the association of PEX5 with 
peroxisomes, demonstrating that these peroxins are not 
required for receptor docking. These and other results 
lead us to propose that PEX12 and PEX10 play direct 
roles in peroxisomal matrix protein import downstream 
of the receptor docking event.
Key words: PTS1 receptor • PEX5 • PEX10 • Zell-
weger syndrome • peroxisome biogenesis disorder
 
S
 
UBCELLULAR
 
 organelles are a defining feature of eu-
karyotes and make essential contributions to virtu-
ally all aspects of cellular metabolism. Although
 
each organelle is physically and chemically unique, there
are several common aspects to the biogenesis of all mem-
brane-limited compartments. One is that all or most of their
protein content must be imported. The protein uptake
mechanisms used in the biogenesis of each organelle must
account for the recognition of newly synthesized proteins
that are destined for each organelle, the transport of these
proteins to the surface of the appropriate compartment,
and the vectorial translocation of these proteins across one
or more lipid bilayers (Schatz and Dobberstein, 1996).
Several paradigms for protein import into organelles
have emerged from studies of the ER (Matlack et al.,
1998), the mitochondrion (Pfanner et al., 1997), and the
nucleus (Mattaj and Englmeier, 1998). However, the pro-
cess of peroxisomal protein import does not conform to
any of these paradigms (Subramani, 1993): proteins are
posttranslationally imported into the peroxisome but co-
translationally inserted into the ER; peroxisomes can im-
port completely folded proteins, internally cross-linked
isopeptide complexes, and even gold particles, whereas
the ER and mitochondria can only accommodate unfolded
precursors; and peroxisomes lack detectable pores, whereas
the nucleus utilizes large gated pores to allow entry of
folded import substrates. Thus, the elucidation of peroxi-
somal protein import mechanisms will undoubtedly reveal
new concepts in organelle biogenesis.
Peroxisomal proteins are encoded by nuclear genes, syn-
thesized in the cytoplasm, and imported posttranslation-
ally into peroxisomes (Lazarow and Fujiki, 1985). Peroxi-
somal matrix proteins contain either of two peroxisomal
targeting signals, the PTS1 (Gould et al., 1989) and PTS2
(Swinkels et al., 1991). Although either of these signals is
sufficient to direct proteins into the peroxisome matrix,
the vast majority of peroxisomal matrix proteins utilize the
COOH-terminal PTS1 rather than the NH
 
2
 
-terminal PTS2
(Subramani, 1993). These signals are recognized by PEX5
and PEX7, the physical receptors for the PTS1 and PTS2,
respectively (McCollum et al., 1993; Marzioch et al., 1994;
Distel et al., 1996). In contrast, integral peroxisomal mem-
brane proteins (PMPs)
 
1
 
 do not use either PTS1 or PTS2
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motifs for targeting and are efficiently imported into per-
oxisomes independently of PEX5 and PEX7 (Subramani,
1993; Dyer et al., 1996; Chang et al., 1999).
Current models of peroxisomal matrix protein import
are heavily influenced by the fact that PEX5 is a predomi-
nantly cytoplasmic protein in several species (Dodt et al.,
1995; Wiemer et al., 1995; Elgersma et al., 1996; Gould
et al., 1996) and appears to cycle between the cytoplasm
and peroxisomes in mammalian cells (Dodt and Gould,
1996). The dynamic distribution of the PTS1 receptor
implies that peroxisomal matrix protein import involves
overlapping cytoplasmic and peroxisomal events in addi-
tion to the actual translocation process (Braverman et al.,
1995; Rachubinski and Subramani, 1995). Before translo-
cation, import of PTS1-containing proteins (ligands) is
likely to involve recognition by PEX5 in the cytoplasm,
followed by transport of the receptor–ligand complex to
the peroxisome surface and binding of the receptor–ligand
complex to docking factors on the peroxisome membrane.
After ligand translocation, additional factors are thought
to mediate the recycling of PEX5 back to the cytoplasm.
PEX14, PEX13, and PEX17 have been implicated in re-
ceptor docking (Elgersma et al., 1996; Erdmann and Blo-
bel, 1996; Gould et al., 1996; Albertini et al., 1997; Huhse
et al., 1998; Girzalsky et al., 1999), and PEX4 has been re-
ported to act in the recycling of PEX5 from the peroxi-
some to the cytoplasm (van der Klei et al., 1998). Other
 
PEX
 
 genes such as 
 
PEX1
 
 (Portsteffen et al., 1997; Reuber
et al., 1997; Chang et al., 1999), 
 
PEX2
 
 (Shimozawa et al.,
1992; Chang et al., 1999), 
 
PEX6
 
 (Yahraus et al., 1996;
Chang et al., 1999), 
 
PEX10
 
 (Kalish et al., 1995; Warren et al.,
1998; Chang et al., 1999), and 
 
PEX12
 
 (Kalish et al., 1996;
Chang et al., 1997; Chang and Gould, 1998; Chang et al.,
1999) have also been implicated in peroxisomal matrix
protein import. However, their roles in matrix protein im-
port are only poorly understood and other reports have
suggested that 
 
PEX1
 
 and 
 
PEX6
 
 may instead participate in
the biogenesis of peroxisome membranes (Erdmann et al.,
1991; Spong and Subramani, 1993; Heyman et al., 1994;
Titorenko et al., 1997; Faber et al., 1998; Titorenko and
Rachubinski, 1998a,b).
Although most 
 
PEX
 
 genes were originally identified in
yeast, our understanding of peroxisome biogenesis has
also been advanced by the analysis of this process in hu-
mans and how it is disrupted in the peroxisome biogenesis
disorders (PBDs) (Lazarow and Moser, 1995). Zellweger
syndrome, neonatal adrenoleukodystrophy, and infantile
Refsum disease represent a phenotypic continuum of dis-
eases within the PBDs that we refer to as the Zellweger
spectrum. Their clinical phenotypes include developmen-
tal delay, multiple neural, hepatic, and renal defects, and
pronounced mental retardation. These clinical phenotypes
are most severe in Zellweger syndrome patients, who
rarely survive their first year, are milder in neonatal adre-
noleukodystrophy, and even less pronounced in infantile
Refsum disease. At the cellular level, virtually all Zell-
weger spectrum patients display defects in the import of
both PTS1 and PTS2 proteins, though there are rare pa-
tients who are defective only in PTS1 protein import
(Slawecki et al., 1995). There is significant genetic hetero-
geneity within the Zellweger spectrum and recent studies
have identified the genes that are mutated in 
 
.
 
95% of
PBD patients and nine of the eleven known PBD comple-
mentation groups. These include 
 
PEX1 
 
(Portsteffen et al.,
1997; Reuber et al., 1997), 
 
PEX2 
 
(Shimozawa et al., 1992),
 
PEX5 
 
(Dodt et al., 1995), 
 
PEX6 
 
(Fukuda et al., 1996;
Yahraus et al., 1996), 
 
PEX10 
 
(Okumoto et al., 1998a;
Warren et al., 1998), 
 
PEX12 
 
(Chang et al., 1997; Okumoto
et al., 1998b), 
 
PEX13 
 
(Liu et al., 1999; Shimozawa et al.,
1999), 
 
PEX16 
 
(Honsho et al., 1998; South and Gould,
1999), and 
 
PEX19 
 
(Matsuzono et al., 1999). Variations in
the clinical and cellular phenotypes within the Zellweger
spectrum are related primarily to the severity of the af-
fected alleles, with mild phenotypes arising from 
 
PEX
 
gene mutations that only partially reduce 
 
PEX
 
 gene func-
tion (Reuber et al., 1997; Chang and Gould, 1998; Col-
lins and Gould, 1999). In contrast to the Zellweger spec-
trum of diseases, rhizomelic chondrodysplasia punctata is
caused by mutations in 
 
PEX7
 
, which encodes the PTS2 re-
ceptor (Braverman et al., 1997; Motley et al., 1997; Purdue
et al., 1997).
We initially identified 
 
PEX12
 
 in the yeast 
 
Pichia pas-
toris
 
 as a gene that is required for normal peroxisome bio-
genesis (Kalish et al., 1996). More recent studies have de-
scribed the human homologue of this gene and reported
that mutations in 
 
PEX12
 
 are responsible for complemen-
tation group 3 of the PBDs (Chang et al., 1997; Okumoto
and Fujiki, 1997; Chang and Gould, 1998; Okumoto et al.,
1998b). Both yeast and human 
 
PEX12
 
 encode an integral
peroxisomal membrane protein with a zinc ring motif at its
COOH terminus (Kalish et al., 1996; Okumoto and Fujiki,
1997). These studies also established that PEX12 spans the
peroxisome membrane twice and extends its NH
 
2 
 
and
COOH termini into the cytoplasm. In this report, we in-
vestigate the function of human PEX12 in peroxisome bio-
genesis. We find that PEX12 interacts with PEX5 and
PEX10 via its COOH-terminal zinc-binding domain, that
these interactions are biologically significant, and that
PEX12 and PEX10 participate in an aspect of peroxisomal
matrix protein import that occurs downstream of receptor
docking.
 
Materials and Methods
 
Cell Lines, Transfections, and 
Indirect Immunofluorescence
 
Skin fibroblast cell lines from patients with peroxisome biogenesis disor-
ders are referred to by their PBD numbers and were cultured in complete
medium (DME supplemented with 10% FBS and penicillin/streptomy-
cin). Transfections were performed by electroporation using the protocol
outlined by Chang et al. (1997) and were processed 2 d later for immuno-
fluorescence. Immunofluorescence experiments were performed essen-
tially as described (Slawecki et al., 1995). In brief, cells were grown on
cover glasses, fixed, permeabilized, washed, incubated with the primary
antibodies, washed extensively, incubated with the secondary antibodies,
washed extensively, and then mounted on glass slides. Standard permeabi-
lization was for 5 min with 1% Triton X-100, which permeabilizes both
plasma and peroxisome membranes. Differential permeabilization was for
2–4 min with 25 
 
m
 
g/ml digitonin, which permeabilizes the plasma mem-
brane but does not permeabilize the peroxisome membrane. Hence, only
cytoplasmically exposed antigens can be detected under these conditions.
Differential permeabilization experiments were generally performed with
additional controls to ensure that the incubation in digitonin had not per-
meabilized any intracellular membranes. Rabbit polyclonal antibodies
against the PTS1 tripeptide ser-lys-leu-COOH have been described
(Gould et al., 1990) and the anti-human PEX5 antibodies were generated 
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against bacterially expressed forms of the protein. Mouse mAbs against
the c-myc epitope were obtained from the tissue culture supernatant of
the hybridoma 1-9E10 (Evan et al., 1985). Rabbit polyclonal antibodies
against c-myc, sheep anti-human catalase antibodies, and fluorescently la-
beled secondary antibodies were obtained from commercial sources.
 
Mutation Detection
 
We previously described a mutation detection strategy for human 
 
PEX12
 
(Chang et al., 1997; Chang and Gould, 1998). In brief, the entire 2.3-kb
 
PEX12
 
 gene was amplified from the total human genomic DNA using the
primers Chang-21 and Chang-20 (Table I). The coding regions and intron/
exon junctions were sequenced directly from the PCR product using the
primers used for amplification as well as several additional gene specific
primers (Table I, Chang-17, Chang-24, and Chang-30). Total genomic
DNA was isolated from PBD054 cells using the PureGene kit (Gentra
Systems, Inc.).
 
Plasmids
 
Most of the plasmids used for yeast two-hybrid studies were based on
pPC62, a 
 
LEU2
 
-based GAL4 DNA–binding domain fusion protein ex-
pression vector and pPC86, a 
 
TRP1
 
-based GAL4 transcriptional activa-
tion domain (AD) fusion protein expression vector (Chevray and
Nathans, 1992). These plasmids contain two PvuI sites in symmetric posi-
tions, and the PvuI fragments of these plasmids were switched to create
pJL59 (Vidal et al., 1996) and pPC86/L2. The plasmid pJL59 is identical to
pPC62 except that it contains the 
 
TRP1
 
 gene in place of the 
 
LEU2
 
 gene,
and pPC86/L2 is identical to pPC86 except that it contains the 
 
LEU2
 
 gene
in place of the 
 
TRP1
 
 gene. The plasmid pGAD424 (CLONTECH Labo-
ratories) was also used for expression of some GAL4-AD fusion proteins.
The plasmid pJL59-
 
PEX12C
 
 was created by amplifying a subregion of
 
PEX12
 
 using the primers 12.2HC5
 
9
 
 and 12.2H3
 
9
 
 (Table I) and pcDNA3-
 
PEX12
 
 as the template (Chang et al., 1997), cleaving the resulting 370-bp
product with SalI and NotI, and inserting this fragment between the SalI
and NotI sites of pJL59. This plasmid is designed to express a fusion be-
tween the GAL4 DNA–binding domain and amino acids 260–359 of hu-
man PEX12. The plasmid pJL59-
 
PEX12C
 
/S320F was created using the
same cloning strategy except that pcDNA3-
 
PEX12
 
/S320F (see below) was
used as the template. The plasmid pPC86/L2-
 
PEX10C
 
 was created by am-
plifying a subregion of 
 
PEX10
 
 using the primers 10.2HC5
 
9
 
 and 10.2H3
 
9
 
(Table I) and pcDNA3-
 
PEX10
 
 (Warren et al., 1998) as the template,
cleaving the resulting 327-bp product with SalI and NotI, and inserting
this fragment between the SalI and NotI sites of pJL59. This plasmid is de-
signed to express a fusion between the COOH-terminal 87 amino acids of
human PEX10 and the GAL4 activation domain. The plasmid pPC86/L2-
 
PEX14
 
 encodes a fusion between the GAL4 activation domain and full-
length PEX14 and was created by amplifying the entire 
 
PEX14
 
 open read-
ing frame (ORF) using the primers 14.2H5
 
9
 
 and 14.2H3
 
9
 
 (Table I) and
total human cDNA as a template, cleaving the resulting product with SalI
and NotI, and inserting this fragment between the SalI and NotI sites of
pPC86/L2. The PEX5 two-hybrid plasmids were created as follows. The
entire 
 
PEX5
 
S ORF was excised from plasmid pGD100 (Dodt et al., 1995)
by cleavage with NcoI, after which the ends were made blunt with the Kle-
now fragment of DNA PolI and dNTPs, and then cleavage with BglII. The
resulting 2-kb 
 
PEX5
 
S fragment was isolated and inserted between the
 
SmaI and BglII sites of pGAD424, downstream of and in-frame with
the  GAL4 transcription activation domain. The resulting plasmid,
pGAD424-PEX5S, encodes a fusion between the GAL4 activation do-
main and full-length PEX5S. The plasmid pGAD424-
 
PEX5
 
L was created
by cleaving pPEX5L (Braverman et al., 1998) with NcoI, making the ends
blunt with the Klenow fragment of DNA PolI and dNTPs, cleaving this
DNA with BglII, isolating the resulting 2-kb 
 
PEX5
 
L fragment, and insert-
ing it between the SmaI and BglII sites of pGAD424. The plasmid
pGAD424-
 
PEX5S
 
/
 
D
 
N encodes a fusion protein between the GAL4 tran-
scriptional activation domain and the COOH-terminal 317 amino acids of
PEX5. It was created by excising the NH
 
2
 
 terminally truncated 
 
PEX5
 
fragment from pGD105 (Dodt et al., 1995) with NcoI (after which the
ends were made blunt with the Klenow fragment of DNA PolI and
dNTPs) and BglII and inserting the resulting 1-kb 
 
PEX5
 
 fragment be-
tween the SmaI and BglII sites of pGAD424.
Bacterial expression vectors were based on a derivative of pMAL-c2
(New England Biolabs Inc.), pMBP differs from pMAL-c2 in that it con-
tains a SalI site downstream of the EcoRI site (GAATTCAAGTCGAC,
EcoRI and SalI sites underlined), and a NotI site upstream of the HindIII
site (GCGGCCGCAAGCTT, NotI and HindII sites underlined). pMBP-
PEX12C was created by excising the 
 
PEX12
 
 SalI-NotI fragment from
pJL59-
 
PEX12C
 
 and inserting it between the SalI and NotI sites of pMBP.
pMBP-
 
PEX12C
 
/S320F was created by excising the 
 
PEX12
 
 SalI-NotI frag-
ment from pJL59-
 
PEX12C
 
/S320F and inserting it between the SalI and
NotI sites of pMBP.
All mammalian expression vectors are based on pcDNA3 (Invitrogen
Corp.). We have previously described the expression vectors pcDNA3-
 
PEX5
 
S (pGD100; Dodt et al., 1995), pcDNA3-
 
PEX5
 
L (pPEX5L; Braver-
man et al., 1998), pcDNA3-
 
PEX10
 
 (Warren et al., 1998), and pcDNA3-
 
PEX12
 
 (Chang et al., 1997). To create pcDNA3-
 
PEX12
 
/3xmyc, the
 
PEX12
 
 ORF was amplified using the oligonucleotides Chang-21 and
Chang-10 (Table I) and pcDNA3-
 
PEX12
 
 as a template. These primers ap-
pend an Asp718 site upstream of the ORF and replace the stop codon
with a BamHI site. The resulting PCR fragment was cleaved with Asp718
and BamHI and cloned upstream of the triple c-myc tag in pcDNA3-
3xmyc (Geisbrecht et al., 1998). To create the plasmid pcDNA3-
 
PEX12
 
/
S320F, we first amplified the 
 
PEX12
 
 ORF from PBD054 cDNA. Total
RNA was extracted from PBD054 cells using the PureScript kit (Gentra
Systems, Inc.) and 
 
PEX12
 
 cDNA was synthesized as described (Chang
and Gould, 1998). The 
 
PEX12
 
 ORF was amplified from the first strand
PBD054 
 
PEX12
 
 cDNA using the primers Chang-21 and Chang-20 (Table
I), cleaved with Asp718 and BamHI, and cloned between the Asp718 and
BamHI sites of pcDNA3, generating pcDNA3-
 
PEX12
 
/S320F. The se-
quence of the final plasmid was confirmed to ensure the presence of the
S320F mutation and the absence of any undesired mutations. The plasmid
pcDNA3-3xHA has a 114-bp DNA insert between the Asp718 and XbaI
sites of pcDNA3, which contains a BglII site (AGATCT) immediately up-
stream of short ORF encoding three repeats of the HA epitope tag
(GRIFYPYDVPDYAGYPYDVPDYAGSYPYDVPDYAL
 
STOP
 
, the HA
epitopes are underlined). To create pcDNA3-
 
PEX10
 
/3xHA, we excised
the 
 
PEX10
 
 ORF (lacking its stop codon) from pcDNA-
 
PEX10
 
myc (War-
ren et al., 1998) using the restriction enzymes Asp718 and BamHI, excised
the 3xHA tag from pcDNA3-3xHA by cleavage with BglII and XbaI, and
inserted these fragments in tandem between the Asp718 and XbaI sites of
pcDNA3.
The regions of all plasmids that were generated by PCR were se-
quenced to confirm the absence of any unintended mutations. Any plas-
mids that did contain undesired mutations were discarded and additional
clones were characterized until one with the desired sequence was ob-
tained.
 
Two-Hybrid Analysis
 
The 
 
Saccharomyces
 
 
 
cerevisiae
 
 two-hybrid reporter strain BY3168 was
used for all experiments (Vidal et al., 1996). All strains were grown over-
night on a nitrocellulose filter membrane (Schleicher & Schuell, Inc.) that
was placed on a plate with minimal medium lacking tryptophan and leu-
cine (Sc-W-L). The cells were lysed by submersion in liquid nitrogen, and
activity of the two-hybrid reporter gene 
 
b
 
-galactosidase was assessed by
placing the filter membrane onto a filter paper saturated with 0.1%
5-bromo-4-chloro-3-indoyl 
 
b
 
-
 
D
 
-galactopyranoside (X-gal) in 100 mM po-
tassium phosphate buffer, pH 7.0. The filters were photographed after
color development.
Protein extracts from BY3168 carrying either pJL59-
 
PEX12C
 
 or
pJL59-
 
PEX12C
 
/S320F were prepared according to established protocols
 
Table I. Sequence of Primers Used in this Article
 
Chang-10 5
 
9
 
-CCCGGATCCGTTCTCAGGGGAGTAGAGTTTA-
ATC-3
 
9
 
Chang-17 5
 
9
 
-AAAATCGTTTCCAGCGGG-3
 
9
 
Chang-20 5
 
9
 
-CCAGGATCCGTGAGGATAAGACATGATTCCC-3
 
9
 
Chang-21 5
 
9
 
-CAAGGTACCAAGTGAAAGCCAGTACACGCAG-3
 
9
 
Chang-24 5
 
9
 
-CACAAGTCTCAGAGATTGGC-3
 
9
 
Chang-30 5
 
9
 
-ATGATGCAGCAACCAGCCAG-3
 
9
 
10.2HC5
 
9
 
5
 
9
 
-CCCGTCGACGAGGCAGCGGCAGCGAGCCAGG-3
 
9
 
10.2H3
 
9
 
5
 
9
 
-CCAAGCGGCCGCCGTAGAGGTCATCTGTGTCC-3
 
9
 
12.2HC5
 
9
 
5
 
9
 
-CCCGTCGACGCAGTTCCTTGACTGGTGGTCC-3
 
9
 
12.2H3
 
9
 
5
 
9
 
-CCAAGCGGCCGCTCAGTTCTCAGGGGAGTAGAG-3
 
9
 
14.2H5
 
9
 
5
 
9
 
-CCCGTCGACGGCGTCCTCGGAGCAGGCAGAG-
CAG-3
 
9
 
14.2H3
 
9
 
5
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(Adams et al., 1997). In brief, the yeast were grown in 4 ml Sc-W-L me-
dium to an OD600 of 2. The cells were transferred to a solution containing
50 mM Tris, pH 7.5, and 10 mM sodium azide, and then pelleted by cen-
trifugation (5,000 g) for 10 min. The pellets were resuspended in 30 ml of
ESB (80 mM Tris, pH 6.8, 1.5% DTT, 2% SDS, 10% glycerol, and 0.1 mg/ml
bromophenol blue), and immediately boiled for 3 min. The tubes were
cooled on ice, and then mixed vigorously with 0.1 g of 425–600-micron
glass beads (Sigma Chemical Co.) for 2 min to lyse the cells. The resulting
lysates were added to an additional 70 ml of ESB and boiled for 1 min.
Equal amounts of each sample were separated by SDS-PAGE, trans-
ferred to Immobilon-P membranes (Millipore), and probed with antibod-
ies raised against the COOH-terminal 17 amino acids of human PEX12 (a
segment that is not present in yeast PEX12).
Protein Purification, In Vitro Translation of Proteins 
and Overlay Assays
A 1-liter culture of DH10B cells (Grant et al., 1990) carrying pMBP-
PEX12C was grown to an OD600 of 0.4, induced with 1 mM isopro-
pyl-b-D-thiogalactopyranoside, and grown overnight at 188C. These cells
were harvested and resuspended in column buffer (20 mM Tris, pH 7.4,
200 mM NaCl, 1 mM EDTA, and 10 mM b-mercaptoethanol) plus 0.5 mg/
ml lysozyme. The cells were frozen in liquid nitrogen, thawed, and lysed
by sonication. The lysate was centrifuged for 20 min at 14,000 g, and the
supernatant was loaded onto a column containing 10 ml of amylose resin.
The column was washed with 12-bed volumes of column buffer and the
protein was eluted with 10 mM maltose. The eluant was collected in 1.5-ml
fractions and the purity was assessed using SDS-PAGE. MBP-PEX12C/
S320F and MBP-LacZa fusion proteins were purified following the same
protocol.
Filter binding experiments were performed as follows. 10 mg of purified
MBP-PEX12C and 10 mg of MBP-LacZa were spotted separately onto
Immobilon-P membranes (Millipore). Two identical membranes were
prepared, one for overlay with HsPEX5S and one for HsPEX5L. The
membranes were allowed to dry for 15 min at room temperature, and then
washed in methanol for 30 s followed by Milli-Q H2O for 1 min. The mem-
branes were transferred to buffer A (50 mM Tris-HCl, pH 7.5, 100 mM
potassium acetate, 150 mM NaCl, 1 mM DTT, 5 mM MgCl2, 1 mM
EDTA, 0.3% [vol/vol] Tween 20, 100 mM ZnCl2, 5% [wt/vol] nonfat milk,
and 100 mM methionine; Fransen et al., 1998) and incubated with shaking
for 1 h at room temperature. Radiolabled HsPEX5S and HsPEX5L were
made using the TNT T7-Quick Coupled in vitro transcription/translation
kit (Promega Corp.) and [35S]methionine (NEN Life Science Products)
according to the manufacturer’s protocols. 20 ml of the in vitro transcrip-
tion/translation reaction was mixed with 5 ml of buffer A plus 10 mg/ml
BSA and incubated with the membrane for 1 h at 378C with shaking. The
membranes were washed twice for 5 min at room temperature with buffer
A, dried, and placed on film.
For assessing the PEX10-PEX12 interaction, 10 mg of purified MBP-
PEX12C and 10 mg of MBP-LacZa were separated by SDS-PAGE and
transferred to Immobilon-P membranes. After transfer, the proteins were
renatured for 2 h at 48C in buffer A. Radiolabeled PEX10 was synthesized
using the TNT T7-Quick Coupled system and [35S]methionine as de-
scribed above. The membranes were incubated overnight at 48C with
shaking in 5 ml of buffer A containing 25 ml of the in vitro transcription/
translation reaction. After washing twice with buffer A at room tempera-
ture, the membranes were dried, and bound [35S]PEX10 was detected by
autoradiography.
Immunoprecipitations
Normal human skin fibroblasts were transfected with pcDNA3-PEX12
and pcDNA3-PEX12/3xmyc. 2 d after transfection, cell lysates were pre-
pared from each of the transfected populations by scraping the cells into
TBSN buffer (10 mM Tris, pH 7.8, 150 mM NaCl, 1% NP-40, 5 mM benz-
amidine, 0.2 mg/ml NaF, 25 mg/ml aprotinin, and 62.5 mg/ml leupeptin).
Each cell lysate was mixed with 1 mg of rabbit polyclonal antibodies
against c-myc (Santa Cruz Biotechnology) for 1 h at 48C. Protein A aga-
rose beads were preincubated with 1% BSA, and then incubated with the
lysate–antibody mixture for 1 h at 48C with gentle agitation. The agarose
beads were collected by centrifugation (1,000 g), washed four times with
1 ml of TBSN buffer, and resuspended in 30 ml SDS-PAGE sample buffer.
Equal amounts of each sample were immunoblotted using anti–PEX5 an-
tibodies. For assessing the coimmunoprecipitation between PEX10 and
PEX12, cells were cotransfected with pcDNA3-PEX12 and pcDNA3-
PEX10/3xHA or pcDNA3-PEX12/3xmyc and pcDNA3-PEX10/3xHA.
After preparation of lysates and immunoprecipitation with anti-myc poly-
clonal antibodies, levels of PEX10/3xHA were determined by immuno-
blot using the 12CA5 monoclonal anti–HA antibody (Boehringer Mann-
heim Corp.). Equivalent levels of PEX5 and PEX10/3xHA in the crude
lysates were confirmed by standard immunoblotting techniques.
Cell Fractionation and Protease Protection Assay
Skin fibroblast cells were grown to 90% confluency in 100-mm dishes, re-
moved from the plate by trypsinization, washed, resuspended in lysis
buffer, and lysed in a ball bearing homogenizer as previously described
(Dodt and Gould, 1996). Postnuclear supernatants were prepared by suc-
cessive 1,500 g spins, and then separated into organelle pellets and cytoso-
lic supernatants by centrifugation at 15,000 g for 10 min. To determine the
relative levels of PEX5 in the cytoplasm and peroxisome of human fibro-
blasts, organelle pellets and cytosolic supernatants were prepared as
above, transferred to membranes, and probed with polyclonal anti–PEX5
antibodies. For protease protection experiments, organelle preparations
were derived from PBD006 and PBD054 cells in the same manner and
were each split into eight equal fractions of 8 mg of protein. Triton X-100
was added to four of the eight tubes to a final concentration of 1%. We
placed the samples on ice and added 0, 15, 30, or 60 mg of a trypsin prepa-
ration (Calbiochem-Novabiochem) to the four samples lacking detergent
and the four samples containing detergent. These mixtures were incu-
bated on ice for 20 min. Reactions were terminated by adding a twofold
excess of bovine trypsin inhibitor (Sigma Chemical Co.). Equal amounts
of each sample were processed for immunoblot with anti–PEX5 anti-
bodies.
Results
The Zinc-binding Domain Is Required for
PEX12 Function
We have identified an array of PEX12 mutations that
cause Zellweger syndrome and the milder phenotypic
variants of neonatal adrenoleukodystrophy and infantile
Refsum disease (Chang et al., 1997; Chang and Gould,
1998). To better understand the regions of PEX12 that are
important for its role in peroxisome biogenesis, we com-
pared the deduced products of the PEX12 alleles in se-
verely and mildly affected patients (Fig. 1). Severe defects
in  PEX12 activity were associated with mutations that
truncated PEX12 upstream of the cytoplasmically exposed
zinc ring domain. Furthermore, all moderately and mildly
affected patients expressed at least one PEX12 allele ca-
pable of encoding a protein that contained the COOH-ter-
minal zinc ring domain. This phenotype–genotype corre-
lation suggested that the COOH-terminal zinc-binding
domain is critical for PEX12 function. This hypothesis is
also supported by the results from directed mutagenesis
experiments on PEX12 in both yeast (Kalish et al., 1996)
and mammalian cells (Okumoto et al., 1998b).
PEX12 Binds PEX5, the PTS1 Receptor
Previous studies have suggested that zinc ring domains
may mediate protein–protein interactions (Borden, 1998),
and the important role of this domain in PEX12 suggested
that it may mediate interactions between PEX12 and
other proteins that are involved in peroxisome biogenesis.
We employed the yeast two-hybrid system to search for
such proteins. A fusion between the GAL4 DNA–bind-
ing domain and the COOH-terminal 100 amino acids of
PEX12 was used as bait to screen a library of fusions be-
tween the GAL4-activating domain and all known human
peroxins. We detected a strong interaction between theChang et al. PEX12 Participates in Peroxisomal Matrix Protein Import 765
zinc-binding domain of PEX12 and PEX5, the PTS1 re-
ceptor (Fig. 2 A). Recent studies (Braverman et al., 1998;
Otera et al., 1998) have established that two isoforms of
PEX5, PEX5S and PEX5L, are synthesized in roughly
equivalent levels in human cells, but we did not observe
any difference in the interaction between PEX12 and
PEX5S or PEX5L.
Next, we used a protein binding assay to independently
assess the interaction between PEX12 and PEX5. We gen-
erated a recombinant fusion protein between maltose-
binding protein (MBP) and the COOH-terminal 100
amino acids of PEX12, which includes its zinc-binding do-
main. The resulting protein, MBP-PEX12, was tested for
its ability to bind PEX5 using a filter binding assay. Equal
amounts of purified MBP-PEX12 and an MBP-LacZa fu-
sion protein were spotted onto membranes and subse-
quently probed with 35S-labeled PEX5 that had been syn-
thesized in vitro in a rabbit reticulocyte lysate. PEX5 was
bound by MBP-PEX12 but not by MBP-LacZa, indicating
that PEX12 was capable of binding PEX5 (Fig. 2 B).
To determine whether the physical interaction between
PEX5 and the zinc-binding domain of PEX12 reflected an
association between these proteins in vivo, we tested
whether PEX12 and PEX5 formed a complex of sufficient
stability to withstand coimmunoprecipitation from cell ly-
sates. Human fibroblasts were transfected with either
of two plasmids, pcDNA3-PEX12 or pcDNA3-PEX12/
3xmyc. 2 d after transfection the cells were lysed, the ly-
sates were subjected to immunoprecipitation with anti-
myc polyclonal antibodies, and the immunoprecipitates
were separated by SDS-PAGE and probed with anti–
PEX5 antibodies. Equal amounts of PEX5 were present
in both crude lysates, but PEX5 was immunoprecipitated
only from the lysate of cells expressing PEX12/3xmyc
(Fig. 2 C).
We next mapped the PEX12-binding domain of PEX5
by expressing different regions of PEX5 in the yeast two-
hybrid system and assaying their interaction with the
PEX12 zinc-binding domain. These fragments of PEX5
were also assayed for their ability to interact with PEX14,
a known docking factor for PEX5 (Albertini et al., 1997;
Fransen et al., 1998; Schliebs et al., 1999) (Fig. 2 D). The
PTS1 binding site of PEX5 is contained within its COOH-
terminal half, a region that contains seven tetratricopep-
tide repeats (Dodt et al., 1995; Terlecky et al., 1995). A
fragment of PEX5 containing little more than the PTS1-
binding domain of PEX5 retained full binding to PEX12.
However, it was unable to bind PEX14, as expected from
the recent study by Schliebs et al. (1999) in which the
PEX14 binding sites were localized to the NH2-terminal
half of PEX5. Additional truncation mutants failed to de-
fine a smaller PEX12-binding site within PEX5 (data not
shown).
The Zinc-binding Domain of PEX12 Binds PEX10
In addition to the interaction between PEX12 and PEX5,
the yeast two-hybrid screen also revealed an interaction
between PEX12 and PEX10, an integral PMP that is re-
quired for peroxisomal matrix protein import (Fig. 3 A).
Like PEX12, human PEX10 contains a cytoplasmically ex-
posed zinc ring domain (Warren et al., 1998) and the inter-
action we detected between these two proteins was medi-
ated through their COOH-terminal zinc ring domains
(amino acids 240–326 of PEX10 and 260–359 of PEX12).
Independent biochemical evidence for physical interaction
between PEX12 and PEX10 was obtained using blot over-
lay experiments. Equal amounts of purified, recombinant
MBP-PEX12 and MBP-LacZa were resolved by SDS-
PAGE, immobilized on membranes, and probed with
35S-labeled PEX10 that had been synthesized in vitro in
rabbit reticulocytes (Fig. 3 B). PEX10 was bound by the
MBP-PEX12 fusion protein but not by MBP-LacZa, sug-
gesting specific binding between PEX12 and PEX10. To
assess whether these proteins were present in a complex
in vivo, we transfected normal human fibroblasts with
plasmids designed to express tagged forms of these pro-
teins, PEX12/3xmyc and PEX10/HA, or PEX10/HA and
an untagged version of PEX12. 2 d after transfection, ly-
sates were prepared from the two sets of transfected
cells, subjected to immunoprecipitation using an anti-myc
Figure 1. The deduced PEX12 products of seven
PBD patients. The diagram shows the predicted
protein product of each PEX12 allele. The zinc
ring domain is indicated by a black box and each
of two transmembrane domains is indicated by
the cross-hatched boxes. Straight lines show the
length of additional amino acids that are ap-
pended as a result of frameshifting mutations.
ZS, Zellweger syndrome; NALD, neonatal adre-
noleukodystrophy; and IRD, infantile Refsum
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polyclonal antibody, and then blotted with a monoclonal
anti–HA antibody. Equivalent amounts of PEX10/HA
were detected in both crude lysates, but PEX10/HA was
only detected in the immunoprecipitate from cells express-
ing PEX12/3xmyc. Thus, PEX12 and PEX10 do appear to
be present in a complex in vivo (Fig. 3 C). Control experi-
ments revealed that these tagged forms of PEX12 and
PEX10 have normal activity in vivo. This region of PEX12
failed to interact with any of the remaining 12 human per-
oxins in the yeast two-hybrid assay.
Genetic Interactions between PEX12, PEX10,
and PEX5
The simplest explanation for the physical association of
PEX12 with both PEX5 and PEX10 is that these interac-
tions contribute to the biogenesis of peroxisomes. In such
an instance, we might expect that high dosage, allele-spe-
cific extragenic suppression could be observed among the
Figure 2. PEX12 interacts with PEX5. (A) Re-
sults of two-hybrid studies between PEX12 and
PEX5. Two-hybrid reporter strains expressing
the indicated fusion proteins were transferred to
a nitrocellulose filter, submerged in liquid nitro-
gen to lyse the cells, and assayed for b-galactosi-
dase activity. AD, GAL4 activation domain; and
BD, GAL4-binding domain. (B) Filter binding
experiments with PEX12 and PEX5. Equal
amounts of MBP-LacZa and MBP-PEX12C
were spotted on membranes and probed with
[35S]PEX5S (upper panel) or [35S]PEX5L (lower
panel). (C) PEX5 coimmunoprecipitates with
PEX12/3xmyc. Lysates were prepared from fi-
broblasts that had been transfected with either
pcDNA3-PEX12 or pcDNA3-PEX12/3xmyc.
After immunoprecipitation with anti–myc anti-
bodies, the immunoprecipitates were analyzed
by immunoblot with anti-PEX5 antibodies (up-
per panel). In addition, equal amounts of the
crude lysate before immunoprecipitation were
assayed for PEX5 levels by immunoblot (lower
panel). (D) PEX12 interacts with the PTS1-bind-
ing domain of PEX5. Two-hybrid reporter
strains expressing the indicated fusion proteins
were transferred to a nitrocellulose filter, sub-
merged in liquid nitrogen to lyse the cells, and
assayed for b-galactosidase activity.
Figure 3. The COOH-terminal domain of PEX12 interacts with
the COOH-terminal domain of PEX10 in the yeast two-hybrid
system. Two-hybrid reporter strains expressing the indicated fu-
sion proteins were transferred to a nitrocellulose filter, sub-
merged in liquid nitrogen to lyse the cells, and assayed for
b-galactosidase activity. AD, GAL4 activation domain; and BD,
GAL4-binding domain. (B) PEX10 binds immobilized PEX12C
in vitro. 10 mg of purified MBP-LacZa and purified MBP-
PEX12C were resolved by SDS-PAGE, transferred to mem-
branes, and probed with 35S-labeled PEX10 (upper panel). A du-
plicate gel was stained before transfer with Coomassie blue
(lower panel). (C) Coimmunoprecipitation of PEX10 with
PEX12. Lysates from cells cotransfected with either pcDNA3-
PEX12 and pcDNA3-PEX10/3xHA (left lane) or pcDNA3-
PEX12/3xmyc and pcDNA3-PEX10/3xHA (right lane) were
immunoprecipitated with anti–myc antibodies and analyzed by
immunoblot with anti–HA antibodies. Aliquots of the crude ly-
sates before immunoprecipitation were also assayed for PEX10/
3xHA levels by immunoblot.Chang et al. PEX12 Participates in Peroxisomal Matrix Protein Import 767
corresponding three genes. Therefore, we tested whether
overexpression of any one of these genes could suppress
mutations in either of the other two genes. In brief, fibro-
blast cell lines with mild or severe mutations in PEX12,
PEX10, or PEX5 were transfected separately with expres-
sion vectors designed to express these genes, as well as a
vector control. 2 d later, each cell population was pro-
cessed for indirect immunofluorescence using antibodies
specific for a peroxisomal matrix protein marker, catalase.
The relative rescue activity of each gene in each cell line
was calculated by comparing the frequency of cells import-
ing catalase in each set of transfected cells.
All three patients from complementation group 2 of
the PBDs have mutations in PEX5 (Dodt et al., 1995;
Slawecki et al., 1995). Two of these patients (PBD018 and
PBD093) are homozygous for a PEX5-N489K/N526K mu-
tation (N489/N586 refers to the position of this asparagine
in PEX5S and PEX5L, respectively). The other PEX5-
deficient patient, PBD005, is homozygous for a PEX5 non-
sense mutation, R390ter/R427ter, which inactivates PEX5.
PBD018 and PBD005 cells were transfected with the plas-
mids pcDNA3, pcDNA3-PEX5, pcDNA3-PEX12, and
pcDNA3-PEX10, incubated for 2 d, and then processed
for immunofluorescence using antibodies specific for per-
oxisomal catalase. Although expression of PEX5 effi-
ciently rescued catalase import in both cell lines, PEX12
and PEX10 were unable to restore catalase import in
these lines (data not shown).
We have also characterized eight complementation
group 3 PBD patients, all of whom are mutated in PEX12
(Chang et al., 1997; Chang and Gould, 1998). Fibroblast
cell lines from each of these patients were transfected with
the above vectors, and the import of peroxisomal matrix
proteins was determined in each population of transfected
cells. As expected, pcDNA3-PEX12 efficiently rescued
the peroxisomal protein import defects in all of these cell
lines. However, we failed to observe any evidence for ex-
tragenic suppression in the CG3 cells that were transfected
with the PEX10 or PEX5 expression vectors (data not
shown).
Our previous work has established that PEX10 is the
gene defective in two patients from complementation
group 7 (CG7), PBD052, and PBD100 (Warren et al.,
1998). Although we have yet to identify the PEX10 muta-
tions in four other CG7 patients, we used fibroblasts from
all six available CG7 patients for our studies. Expression
of PEX10 rescued peroxisomal matrix protein import in
all six CG7 cell lines, whereas PEX12 and PEX5 failed to
have any effect on the cytosolic catalase distribution in
five of these cell lines. However, expression of PEX12
clearly led to the restoration of catalase import in PBD054
cells (Fig. 4, A–F). Expression of PEX5 also rescued per-
oxisomal matrix protein import in this cell line, though to a
lesser extent (Table II).
To better understand the molecular basis of the appar-
ent suppression of PEX10 allele(s) by overexpression of
PEX12 or PEX5, we sequenced the PEX10 gene from
PBD054 cells. Surprisingly, we failed to detect any alter-
ation to the gene in this patient. This result, combined with
the fact that PEX12 was more effective than PEX10 at
rescuing peroxisomal protein import in PBD054 cells (Ta-
ble II), led us to consider whether PEX12, rather than
PEX10, might be mutated in PBD054. The PEX12 gene
was amplified from PBD054 genomic DNA and all coding
portions of the gene were sequenced directly from the
PCR products. We detected a missense mutation, S320F,
in the PEX12 gene from this patient and no evidence of
the wild-type sequence, suggesting that this patient was
homozygous for this mutation in PEX12 (Fig. 5 A). Al-
though S320 is a conserved residue of PEX12 from yeast
to humans (always a serine or threonine), missense muta-
tions may be silent. We engineered the S320F mutation
into the PEX12 expression vector and used a functional
complementation assay (Chang et al., 1997; Chang and
Gould, 1998) to assess the effects of this mutation. PEX12-
deficient cells were transfected with pcDNA3, pcDNA3-
PEX12, or pcDNA3-PEX12/S320F, and 2 d after transfec-
tion the percentage of cells importing matrix proteins into
Figure 4. Peroxisomal protein
import in PBD054 cells is re-
stored by expression of PEX10
or PEX12. PBD054 cells were
transfected with pcDNA3 (A
and D), pcDNA3-PEX10 (B and
E), or pcDNA3-PEX12 (C and
F). 2 d after transfection, the
cells were fixed, permeabilized
with Triton X-100, and pro-
cessed for double indirect immu-
nofluorescence using anticata-
lase antibodies (A–C) and
anti–PMP70 antibodies (D–F).
Bar, 25 mm.
Table II. Suppression of Catalase Import Defect in PBD054 
Cells by Overexpression of PEX5 and PEX10
PEX gene
Percent relative activity to restore
catalase import in PBD054 cells*
HsPEX12 100
HsPEX10 40 6 7
HsPEX5S 19 6 9
HsPEX5L 13 6 3
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peroxisomes was determined by immunofluorescence us-
ing antibodies to the peroxisomal matrix protein catalase.
In each of two trials the PEX12/S320F cDNA displayed
10–15% of the rescue activity of the wild-type PEX12
cDNA (data not shown). The fact that the S320F mutation
reduced but did not eliminate PEX12 function was consis-
tent with the relatively mild cellular and clinical pheno-
types of this patient (PBD054 was diagnosed with neo-
natal adrenoleukodystrophy, and a previous study has
demonstrated that PBD054 cells are able to import small
amounts of some peroxisomal matrix proteins [Dodt and
Gould, 1996]).
The ability of PEX10 and PEX5 to suppress the PEX12/
S320F mutation was a clear example of allele-specific sup-
pression rather than bypass suppression since neither
PEX10 nor PEX5 were capable of rescuing peroxisomal
protein import in any cells with severe mutations in
PEX12. This finding, together with the fact that the
PEX12-S320F mutation lies within the zinc-binding do-
main of PEX12, suggested that this mutation might reduce
the interaction between the zinc ring domain of PEX12
and either PEX10 or PEX5. Using the two-hybrid assay
and the blot overlay assay, we observed that the S320F
mutation led to a marked reduction in the PEX12–PEX10
interaction (Fig. 5 B). Similarly, the PEX12/S320F muta-
tion appeared to reduce the interaction between PEX12
and PEX5 in the yeast two-hybrid assay (Fig. 5 C). It is in-
teresting to note that the placement of PBD054 cells into
CG7 of the PBDs was based upon its noncomplementa-
tion with PBD052 cells. PBD052 cells are mutated in
PEX10 and express one allele with a missense mutation
(H290Q) in the PEX10 zinc-binding domain (Warren et al.,
1998). These results indicate that the combination of the
PEX12/S320F and PEX10/H290Q alleles may have a dele-
terious effect on peroxisomal matrix protein import even
in the presence of normal alleles of each gene.
PEX12 Appears to Act Downstream of
Receptor Docking
A variety of earlier studies have established that loss of
PEX12 or PEX10 results in a severe defect in peroxisomal
matrix protein import (Kalish et al., 1995; Liu et al., 1995;
Slawecki et al., 1995; Kalish et al., 1996; Chang et al., 1997;
Okumoto et al., 1998a,b; Warren et al., 1998). It is also
known that PEX12 and PEX10 are not required for syn-
thesis of peroxisome membranes or import of peroxisomal
membrane proteins (Kalish et al., 1995, 1996; Chang et al.,
1997, 1999; Chang and Gould, 1998; Warren et al., 1998).
Furthermore, the morphological abnormalities that have
been reported for peroxisomes in cells lacking PEX12 or
PEX10 are indistinguishable from those of peroxisomes in
PEX5-deficient cells and appear to be a secondary effect
of the metabolic deficiencies that are caused by the matrix
protein import defects in these cells (Baes et al., 1997;
Chang et al., 1999). These results, together with our obser-
vation that PEX12 interacts with both PEX5 and PEX10,
suggest that PEX12 and PEX10 participate in peroxisomal
matrix protein import.
Current models suggest that there may be several steps
of peroxisomal matrix protein import that are limited to
the peroxisome membrane and could, therefore, involve
Figure 5. PBD054 is mutated in PEX12. (A) Sequence chro-
matographs of PEX12 genomic DNA showing the wild-type se-
quence (top) and PBD054 sequence (bottom) in the region cor-
responding to nucleotides 950–968 of the PEX12 ORF. Note the
C to T transition mutation, S320F, which changes the serine
codon TCT to the phenylalanine codon TTT (underlined). (B)
The S320F mutation attenuates the interaction between PEX12
and PEX10. Two-hybrid reporter strains expressing the indicated
fusion proteins were assayed for b-galactosidase activity (top).
To assess the effects of this mutation by blot overlay assay, puri-
fied MBP-LacZa, MBP-PEX12C/S320F, and MBP-PEX12C
were separated by SDS-PAGE, transferred to membranes, and
probed with 35S-labeled PEX10 (upper half of lower panel).
These proteins were also separated by SDS-PAGE and stained
with Coomassie blue (lower half of lower panel). (C) The S320F
mutation attenuates the PEX12-PEX5 interaction in the yeast
two-hybrid assay. Two-hybrid reporter strains expressing the
listed proteins were assayed for b-galactosidase activity (top).
The three strains expressing AD-5S were also lysed and assayed
for BD-PEX12 levels by immunoblot with anti–PEX12 antibodies.Chang et al. PEX12 Participates in Peroxisomal Matrix Protein Import 769
PEX12 or PEX10. These include docking of receptor–
ligand (matrix protein) complexes to the peroxisome, ma-
trix protein translocation across the peroxisome mem-
brane, and receptor recycling (Braverman et al., 1995;
Rachubinski and Subramani, 1995). To distinguish be-
tween these different possibilities, we first tested whether
PEX12 or PEX10 were required for docking of the PTS1
receptor, PEX5, to peroxisomes. Postnuclear supernatants
were prepared from normal human fibroblasts and from a
fibroblast cell line which appears to lack PEX12 activity
altogether (PBD006 [Chang and Gould, 1998]). Peroxi-
somes were pelleted from each postnuclear supernatant by
centrifugation, and the relative amount of PEX5 in the cy-
tosolic supernatant and organelle pellet was determined
by immunoblot. Levels of peroxisome-associated PEX5
were not reduced in the absence of PEX12 or PEX10 and
actually appeared to be slightly elevated in the pex10 and
pex12 mutants (Fig. 6 A). This was also evident in immu-
nofluorescence experiments in which the staining for per-
oxisome-associated PEX5 appeared to be greater in the
pex12 and pex10 mutants than in wild-type cells (Fig. 6,
B–G). These results argue against roles for PEX12 and
PEX10 in PEX5 docking and suggest that they participate
in a downstream step of peroxisomal matrix protein im-
port.
A Missense Mutation in PEX12 Results in
PEX5 Import
Taken together, the properties of PEX12 indicate that it
may participate in peroxisomal matrix protein transloca-
tion rather than receptor docking or recycling (as de-
scribed in Discussion, the phenotypes of PEX12-deficient
cells are not consistent with a role for PEX12 in receptor
recycling). One prediction of this hypothesis is that mild
mutations in PEX12 might alter the properties of the per-
oxisomal matrix protein translocation apparatus without
eliminating translocation altogether. Before our discovery
that PBD054 cells are mutated in PEX12, we reported that
PBD054 cells import PEX5 into the peroxisome lumen
and also import small amounts of some peroxisomal ma-
trix proteins into peroxisomes (Dodt and Gould, 1996).
We revisited the issue of PEX5 distribution in PBD054
cells and also compared it to the distribution of PEX5 in
PBD006 cells. By immunofluorescence studies in which all
cellular membranes are permeabilized, both PBD006 and
PBD054 cells contain detectable levels of peroxisome-
associated PEX5 (Fig. 7, A–D). However, differential per-
meabilization experiments (in which antibodies only have
access to cytoplasmically exposed antigens) revealed that
cytoplasmically exposed PEX5 could still be detected in
PBD006 cells but not in PBD054 cells (Fig. 7, E–H). Simi-
lar results were observed in each of three trials.
These differential permeabilization experiments indi-
cated that PBD006 cells contained more cytoplasmic-
ally exposed PEX5 than PBD054 cells and that PBD054
cells imported PEX5 into the peroxisome lumen. How-
ever, there are two potential caveats to these experiments.
First, immunofluorescence experiments can be influenced
greatly by conformational changes in the antigen, in this
case PEX5. Second, they do not address the question of
whether some of the peroxisomal PEX5 in PBD006 cells
may also be protected from antibodies in the differential
permeabilization experiments. Therefore, we performed
protease protection experiments on organelle prepara-
tions from PBD006 and PBD054 cells. Postnuclear super-
natants were prepared from each cell line, and peroxi-
somes and other large organelles were recovered by
differential centrifugation. These organelle pellets were
resuspended and incubated with various amounts of pro-
tease in the presence or absence of detergent, the reac-
tions were quenched, and each sample was assayed for lev-
els of PEX5 by immunoblot (Fig. 8, A and B). PBD054
cells appeared to contain more protease-resistant PEX5
than PBD006 cells, which may reflect import of PEX5 into
the peroxisome lumen of these cells. Similar results were
obtained in each of three trials.
If PBD054 cells actually do import PEX5 into the perox-
isome lumen, we might expect that peroxisomes of these
cells would contain more PEX5 than those of PBD006
cells. We tested this hypothesis by cell fractionation stud-
ies. Postnuclear supernatants were prepared from wild-
Figure 6. PEX12 and PEX10 are not required for PEX5 docking.
(A) Postnuclear supernatants were separated into cytosolic su-
pernatants (S) and organelle pellets (P). Equal proportions of the
two fractions from each cell line were assayed for PEX5 levels by
immunoblot. Immunofluorescence experiments were performed
with wild-type (B and C), PEX12-deficient PBD006 (D and E),
and PEX10-deficient PBD100 (F and G) cells using anti–PEX5
antibodies (B, D, and F) and anti–PMP70 antibodies (C, E, and
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type, PBD006 and PBD054 fibroblasts, peroxisomes were
separated from cytosol by differential centrifugation, and
the levels of PEX5 in the cytosolic supernatant and
organelle pellet fractions were determined by immuno-
blot. PBD054 cells contained more peroxisome-associated
PEX5, as predicted (Fig. 8 C).
Discussion
In this paper we investigated the role of PEX12 in peroxi-
some biogenesis by examining the phenotypes of PEX12-
deficient cells and identifying peroxins that physically and
genetically interact with PEX12. Previous studies have es-
tablished that loss of PEX12 results in the absence of de-
tectable peroxisomal matrix protein import, but has virtu-
ally no effect on the synthesis of peroxisomes or the
import of peroxisomal membrane proteins (Kalish et al.,
1996; Chang et al., 1997, 1999; Chang and Gould, 1998;
Okumoto et al., 1998b). Such a phenotype alone points to
a role for PEX12 in peroxisomal matrix protein import.
However, the data presented in this report advance this
hypothesis by demonstrating physical and genetic interac-
tion between PEX12 and PEX5, the receptor for newly
synthesized peroxisomal matrix proteins. We detected in-
teractions between PEX12 and PEX5 using the yeast two-
hybrid system, by filter binding assay, in coimmunoprecip-
itation experiments, and by genetic suppression studies.
A Role for PEX12 in Peroxisomal Matrix
Protein Import
It is generally accepted that PEX5 is the receptor for
newly synthesized PTS1-containing proteins (McCollum
et al., 1993; Dodt et al., 1995; Fransen et al., 1995; Terlecky
et al., 1995; Elgersma et al., 1996) and is a predominantly
cytoplasmic protein in mammalian cells (Dodt et al., 1995;
Dodt and Gould, 1996) and several fungal species (van der
Klei et al., 1995; Elgersma et al., 1996; Gould et al., 1996).
Studies in human cells have suggested that PEX5 shuttles
between the cytoplasm and peroxisome (Dodt and Gould,
1996), and several models predict that PEX5 moves
through a variety of steps as it catalyzes peroxisomal ma-
trix protein import. The proportion of PEX5 that resides
in the cytoplasm at steady state probably reflects the needs
of each cell to efficiently capture newly synthesized perox-
isomal matrix proteins (ligands) from the cytoplasm. How-
ever, once these ligands are bound by PEX5 many addi-
tional events must occur. These may be grouped into the
general processes of (1) the transport to and docking of
PEX5–ligand complexes with the peroxisome membrane,
(2) the translocation of ligands into the peroxisome lumen,
and (3) the recycling of receptors back to the cytoplasm
(Braverman et al., 1995; Rachubinski and Subramani,
1995). To distinguish which of these events may involve
PEX12, we considered the phenotypes that are expected
for a mutant in each process and compared them to the
phenotypes of PEX12-deficient cells.
Several studies have implicated the integral peroxisomal
membrane proteins PEX13 and PEX14 in docking of PTS
Figure 7. Distribution of PEX5 in PBD006 and PBD054 cells.
PBD006 (A, B, E, and F) and PBD054 (C, D, G, and H) cells
were fixed, permeabilized with either Triton X-100 (A–D) or dig-
itonin (E–H), and processed for double indirect immunofluores-
cence using anti–PEX5 antibodies (A, C, E, and G) and anti–
PMP70 antibodies (B, D, F, and H). Bar, 25 mm.
Figure 8. Protease protection analysis of peroxisomal PEX5 in
PBD006 and PBD054 cells. Organelle fractions were prepared
from PBD006 (A) and PBD054 (B) cells and incubated with pro-
tease in the absence or presence of detergent, and then assayed
for PEX5 by immunoblot binding. (C) Postnuclear supernatants
from PBD006 and PBD054 cells were separated into cytosolic su-
pernatants (S) and organelle pellets (P). Equal proportions of
each were assayed for PEX5 levels by immunoblot.Chang et al. PEX12 Participates in Peroxisomal Matrix Protein Import 771
receptors to the peroxisome membrane (Elgersma et al.,
1996; Erdmann and Blobel, 1996; Gould et al., 1996; Al-
bertini et al., 1997; Girzalsky et al., 1999). The defining
features of these docking factors are as follows: (1) their
ability to bind PEX5 and PEX7, either directly or indi-
rectly, and (2) the fact that loss of PEX13 or PEX14 results
in a significant reduction in the amount of peroxisome-
associated PEX5. The fact that loss-of-function mutations
in PEX12 do not result in any detectable reduction in the
levels of peroxisome-associated PEX5 argues strongly
against the hypothesis that PEX12 participates in receptor
docking. In fact, our data indicate that the loss of PEX12
may actually increase the levels of peroxisome-associated
PEX5. This observation, together with the fact that recep-
tor docking is the first peroxisome-localized step of perox-
isomal matrix protein import, demonstrates that PEX12
acts downstream of the docking event. Thus, PEX12 ap-
pears to be the first known PEX5-binding protein that is
not required for docking the PTS1 receptor to the peroxi-
some.
Of the two remaining aspects of peroxisomal matrix
protein import, protein translocation and receptor recy-
cling, there is no report of a bona fide protein transloca-
tion factor, but there is one report that proposes a role for
PEX4 in receptor recycling (van der Klei et al., 1998). This
conclusion was based in part on the phenotypes of pex4
mutants, which display a very mild defect in peroxisomal
matrix protein import and can be suppressed by overex-
pression of PEX5. However, we observed that cells lack-
ing human PEX12 display a severe defect in peroxisomal
matrix protein import that cannot be suppressed by over-
expression of PEX5. Thus, PEX12 does not have the prop-
erties we might expect of a factor that is required for re-
ceptor recycling.
The remaining aspect of peroxisomal matrix protein im-
port to consider is the protein translocation process. Actu-
ally, a role for PEX12 in peroxisomal matrix protein trans-
location would fit well with the known properties of this
protein. First, PEX12 has the appropriate physical charac-
teristics for such a role: it is an integral peroxisomal mem-
brane protein that spans the membrane twice and extends
its NH2 and COOH termini toward the cytoplasm where
they may interact with other protein import factors (Ka-
lish et al., 1996; Chang et al., 1997; Okumoto and Fujiki,
1997). Second, it utilizes its COOH-terminal zinc-binding
domain to interact with PEX5, the PTS1 receptor. Third,
cells with inactivating mutations in PEX12 are unable to
import peroxisomal matrix proteins but do synthesize per-
oxisomes and import integral peroxisomal membrane pro-
teins (Kalish et al., 1996; Chang et al., 1997, 1999; Chang
and Gould, 1998). Fourth, PEX12 interacts with PEX10,
another integral peroxisomal membrane protein that dis-
plays a specific defect in the import of peroxisomal matrix
proteins (Kalish et al., 1995; Warren et al., 1998) and yet
does not appear to participate in receptor docking or recy-
cling. Fifth, a missense mutation in PEX12, S320F, ap-
pears to affect the specificity of the translocation appara-
tus, resulting in the import of PEX5 into the peroxisome
lumen.
Although there is no established in vitro protein translo-
cation assay that can be used to test this hypothesis di-
rectly, it is useful to consider possible roles for PEX12 in
the translocation process. The main function of a matrix
protein translocon would be to move matrix proteins from
the cytoplasmic side of the peroxisome membrane to the
lumenal side. Given that most of these proteins arrive at
the peroxisomes in a complex with PEX5 and that studies
of Yarrowia lipolytica PEX5 strongly suggest that PEX5
participates in the matrix protein translocation process
(Szilard et al., 1995), we favor a model for matrix protein
translocation that includes PEX5. Such a model may in-
volve: (1) acceptance of PEX5–ligand complexes from
PEX14, the primary PEX5 docking site; (2) retention of
PEX5 at the translocation apparatus; (3) opening of the
matrix protein translocation pathway; (4) PEX5–ligand
dissociation and ligand translocation; (5) closure of the
translocation pathway; and (6) release of the unoccupied
receptor from the translocation apparatus. The ability of
PEX12 to bind PEX5 suggests that PEX12 may contribute
to retaining PEX5 at the translocation apparatus. Some
additional support for this hypothesis comes from the fact
that PEX5 appears to be imported into the peroxisome as
a result of the PEX12/S320F mutation, which reduces the
interaction between PEX12 and PEX5.
This model predicts that PEX5 enters the peroxisomal
compartment during the normal course of peroxisomal
matrix protein import. However, it also predicts that
PEX5 should normally be retained at the translocation ap-
paratus rather than being released to move freely through
the peroxisome lumen. A low rate of PEX5 release from
the translocation apparatus into the lumen could explain the
detection of intraperoxisomal PEX5 in Hansenula poly-
morpha (van der Klei et al., 1995). Y. lipolytica PEX5,
which is detected only on or in the peroxisome, could also
function within such a model, provided that it participates
in just the peroxisome-limited steps of matrix protein im-
port (Szilard et al., 1995).
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